Article
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
The New England journal of medicine - 29 Oct 2015
Mateo Joaquin, Carreira Suzanne, Sandhu Shahneen, Miranda Susana, Mossop Helen, Perez-Lopez Raquel, Nava Rodrigues Daniel, Robinson Dan, Omlin Aurelius, Tunariu Nina, Boysen Gunther, Porta Nuria, Flohr Penny, Gillman Alexa, Figueiredo Ines, Paulding Claire, Seed George, Jain Suneil, Ralph Christy, Protheroe Andrew, Hussain Syed, Jones Robert, Elliott Tony, McGovern Ursula, Bianchini Diletta, Goodall Jane, Zafeiriou Zafeiris, Williamson Chris T, Ferraldeschi Roberta, Riisnaes Ruth, Ebbs Bernardette, Fowler Gemma, Roda Desamparados, Yuan Wei, Wu Yi-Mi, Cao Xuhong, Brough Rachel, Pemberton Helen, A'Hern Roger, Swain Amanda, Kunju Lakshmi P, Eeles Rosalind, Attard Gerhardt, Lord Christopher J, Ashworth Alan, Rubin Mark A, Knudsen Karen E, Feng Felix Y, Chinnaiyan Arul M, Hall Emma, de Bono Johann S
Abstract excerpt
BACKGROUND: Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib. METHODS: We conducted a phase 2 trial in which patients with metastatic, castration-resistant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.